Figure 1From: Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA studyThe TRYPHAENA study design. (Biomarker assessments are indicated by arrows).Back to article page